A Louisiana woman is suing the makers of two type 2 diabetes drugs used off-label for obesity, saying they failed to adequately warn about the risk of severe stomach problems. The lawsuit seeks “very significant” but unspecified compensation from the makers of both Ozempic and Mounjaro, said attorney Paul Pennock of the Orlando, Fla.-based firm Morgan & Morgan.
Author: Abhay Panchal
In a Healio video exclusive, Edward V. Loftus Jr., MD, highlighted the growing recognition that diet, specifically tailored nutrition interventions, can play a crucial role in the management of several gastrointestinal disorders. “We all know, especially in [inflammatory bowel disease], the re-emerging of diet as an important factor in terms of how to manage patients, and I think that recognition has played out in other parts of GI as well,” Loftus, the Maxine and Jack Zarrow Family Professor of Gastroenterology at the Mayo Clinic told Healio.
Compare hospital ratings for gastroenterology and GI surgery. U.S. News evaluated 1,581 hospitals and ranked the top 50 that treat many challenging patients for stomach, esophageal, digestive, pancreatic, liver, colon, bowel and rectal procedures and conditions such as IBD, cirrhosis and hepatitis.
Colon cancer remains the second deadliest cancer in the U.S. in 2023, but it has a 90 percent survival rate with early detection and treatment. In the last year, five celebrities have publicly shared their colonoscopy journeys in an effort to encourage the general public to get checked for colorectal cancer.
Some clinicians say it’s “confusing” and “ridiculous” to change the name and diagnostic criteria of an established liver disease, while others bemoan the seemingly political reasons why it happened. Yet recently, 236 panelists from 56 countries decided that the terms nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) rely on “exclusionary confounder terms and the use of potentially stigmatizing language.” In a report published June 24 in the Journal of Hepatology, the panelists, members of the NAFLD Nomenclature Consensus Group, determined that steatotic liver disease (SLD) would be used as an “overarching term to encompass the various etiologies of…
IBS is a symptom-based disorder characterized by recurring bouts of abdominal pain and altered bowel habits. IBS is prevalent, negatively affects quality of life and work productivity, and accounts for billions of dollars in healthcare expenditures. IBS is effectively treated with individualized combinations of medications, diet changes and behavioral interventions. The review is intended to familiarize gastroenterologists with the current generation of DTx that provide virtual behavioral health interventions for patients with IBS.
A clinical trial is one of the most essential steps in the pharmaceutical/biotechnology research and development process, yet one of the biggest stumbling blocks historically has been finding and retaining patients to participate in studies. The answer to that problem could lie in helping more physicians integrate clinical trials into their private community practices to make it a natural extension of the routine care they provide their patients.
Second-quarter 2023 highlights
The FDA approved trifluridine and tipiracil with bevacizumab for patients with previously treated metastatic colorectal cancer. The approval applies to use of the combination by patients who received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy and — if RAS wild-type — an anti-EGFR therapy.
Burden of NAFLD in the U.S.Nonalcoholic fatty liver disease (NAFLD) has become a rapidly increasing public health burden in the U.S. and elsewhere. NAFLD is a manifestation of systemic metabolic abnormalities, including insulin resistance, dyslipidemia, central obesity, and hypertension. In this short review, we summarize data on the burden of NAFLD in the U.S. and its prognostic determinants and review what clinical and public health approaches may be needed to mitigating its impact.